Asymchem Laboratories (Tianjin) (002821) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached ¥1.54 billion, up 10.10% year-over-year, with net profit attributable to shareholders at ¥326.61 million, up 15.83% year-over-year, indicating solid growth despite a slow industry recovery.

• The company advanced cost reduction and efficiency initiatives, and new business segments such as peptides, oligonucleotides, and ADCs saw revenue growth exceeding 80% year-over-year.

Financial highlights

• Operating cash flow was ¥449.34 million, down 8.42% year-over-year.

• Basic and diluted EPS were both ¥0.89, up from ¥0.76 in the prior year.

• Total assets at quarter-end were ¥19.45 billion, up 0.82% from year-end 2024.

• Shareholders’ equity increased 1.99% to ¥17.18 billion.

• Gross margin for small molecule business was 45.17%; new business gross margin was 33.05%, showing improvement.

Outlook and guidance

• The company expects continued positive momentum for the full year, building on Q1’s dual growth in revenue and profit.